Entresto Tablet, Film Coated
Product Images NDC 0078-0696

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Entresto (NDC 0078-0696). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Valsartan Structural Formula (Entresto 01)

Chemical structure diagram of sacubitril and valsartan, showing structural formulas including aromatic rings, nitrogen atoms, carboxylate groups, and associated molecular features.*

FDA Label Image

Figure 1: Effect Of Entresto On Pharmacokinetics Of Coadministered Drugs (Entresto 02)

A chart showing the geometric mean ratio and 90% confidence intervals for the pharmacokinetic parameters AUC and Cmax of various coadministered drugs relative to a reference. The drugs listed include Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Atorvastatin, and Sildenafil. The x-axis represents change relative to reference from 0.5 to 2.*

FDA Label Image

Figure 2: Pharmacokinetics Of Entresto In Specific Populations (Entresto 03)

A pharmacokinetic chart showing geometric mean ratios and 90% confidence intervals for AUC and Cmax comparing LBQ657 and Valsartan under various population conditions including renal impairment levels, hepatic impairment levels, age groups, sex, and ethnicities. The chart plots change relative to reference on a logarithmic scale from 0.5 to 4.*

FDA Label Image

Figure 3: Kaplan-meier Curves For The Primary Composite Endpoint (a), Cardiovascular Death (b), And Heart Failure Hospitalization (c) (Entresto 04)

Three Kaplan-Meier cumulative failure rate graphs compare ENTRESTO and Enalapril over time in days. Figure A shows time to first occurrence of cardiovascular death or heart failure hospitalization. Figure B shows time to cardiovascular death, and Figure C shows time to first heart failure hospitalization, with hazard ratios indicating lower risk for ENTRESTO in each.*

FDA Label Image

Figure 4: Primary Composite Endpoint (cv Death Or Hf Hospitalization) (Subgroup Analysis)

A forest plot chart comparing the hazard ratio and 95% confidence intervals of ENTRESTO versus Enalapril across various subgroups. The subgroups include age, gender, weight, race, region, NYHA class, estimated GFR, diabetes, systolic blood pressure, ejection fraction, atrial fibrillation, NT-proBNP level, hypertension, prior use of ACE inhibitor/ARB/aldosterone antagonist, prior hospitalization for heart failure, time since diagnosis, cause of heart failure, and presence of ICD. The x-axis represents hazard ratio values, where values left of 1 indicate ENTRESTO is better, and values right indicate Enalapril is better.*

FDA Label Image

Entresto 06

ENTRESTO 24 mg/26 mg film-coated tablets label by Novartis Pharmaceuticals Corporation. The label shows the product name, active ingredients sacubitril and valsartan, strength, Rx only designation, and a count of 60 tablets. It includes storage instructions, manufacturer and distributor information, and a barcode on the left side.*

FDA Label Image

Entresto 07

ENTRESTO 49 mg/51 mg film-coated tablets packaging label, containing 60 tablets. The label shows the brand name, active ingredients sacubitril and valsartan, and prescription information. It includes storage instructions, manufacturer details from Novartis Pharmaceuticals, and a barcode with NDC 0078-0777-20.*

FDA Label Image

Entresto 08

ENTRESTO 97 mg/103 mg tablets film coated container label by Novartis Pharmaceuticals Corporation. This Rx only oral medication bottle contains 60 tablets of sacubitril and valsartan. The label includes dosage storage instructions and manufacturer information.*

FDA Label Image

Entresto 09

A line graph titled 'Total Heart Failure Hospitalizations and CV Death in PARAGON-HF' showing the mean number of events per 100 patients over time since randomization (in days). Two lines compare outcomes between patients taking ENTRESTO and those taking Valsartan, with ENTRESTO showing a consistently lower mean number of events. The graph includes numbers of patients at risk at several time points.*

FDA Label Image

Entresto 10

A forest plot comparing rate ratios of ENTRESTO versus Valsartan across multiple patient subgroups. The chart displays subgroups by age, gender, race, region, baseline conditions, and clinical parameters. Each subgroup includes point estimates with confidence intervals favoring either ENTRESTO or Valsartan.*

FDA Label Image

Entresto 11

The image contains two line graphs labeled PARADIGM-HF and PARAGON-HF, comparing ENTRESTO versus enalapril and ENTRESTO versus valsartan, respectively. Both graphs plot hazard ratio on the vertical axis against left ventricular ejection fraction at screening (%) on the horizontal axis. Each graph includes a solid line representing the hazard ratio and dashed lines indicating the 95% confidence interval.*

FDA Label Image

Entresto 12

Label for Entresto 24 mg/26 mg film-coated tablets including the active ingredients sacubitril and valsartan. The package contains 28 tablets and is marked as a physician sample not for sale. The label features the Novartis logo and states Rx only.*

FDA Label Image

Entresto 13

Label for Entresto (sacubitril and valsartan) tablets, film coated, 49 mg/51 mg strength. The label indicates it is a physician sample not for sale, contains 28 tablets, and is labeled for prescription use only. The manufacturer is Novartis Pharmaceuticals Corporation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.